Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. The global conjugate vaccine market is expected to grow at a CAGR of 14.6%, leading to a global revenue of USD 100.59 Bn by 2023. By volume, it is anticipated to reach 9600.56 Million units by 2023, expanding at a CAGR of 17.2%.
The conjugate vaccine market is classified into two primary segments-based on disease indication: pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others; and based on end user: paediatric and adult. Asia-Pacific will have the highest CAGR during the forecasted period.
Key growth factors:
o Rising adoption of cancer therapeutic vaccines, improvement in patient compliance along with an increasing product pipeline, and growing efforts for the adoption of appropriate preventive screening methods to help avert adverse reactions will accelerate the market.
o Conjugate Vaccine market is expected to have positive growth owing to technological advancements, growth initiatives for the production of low-cost vaccines, and widespread routine vaccination programs in emerging economies.
Threats and key players: o Although the conjugate vaccine market is expected to have a positive growth globally, lack of awareness, shortage risk, the situation of oligopoly, uncertainty about the future of international initiatives, emerging manufacturers, and costs and prices of new vaccines will hinder growth.
o Major Conjugate Vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, Novartis, etc.
What’s covered in the report? 1. Overview of the global conjugate vaccine market 2. Market drivers and challenges in the global conjugate vaccine market 3. Market trends in the global conjugate vaccine market 4. Historical, current and forecasted market size data for the global disease indication segment (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume 5. Historical, current and forecasted market size data for the global end user segment (paediatric and adult conjugate vaccines) – by revenue and by volume 6. Historical, current and forecasted regional (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) market size data for the conjugate vaccine market – by revenue and by volume 7. Historical, current and forecasted market size data for the region-wise conjugate vaccine market segments – by revenue and by volume 8. Analysis of the competitive landscape and profiles of major companies operating in the market
o Understand the demand for conjugate vaccines to determine the viability of the market o Determine the developed and emerging markets where conjugate vaccines are provided o Identify the challenge areas and address them o Develop strategies based on the drivers, trends and highlights for each of the segments o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed o Recognize the key competitors of this market and respond accordingly o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth o Define the competitive positioning by comparing the products and services with the key players in the market
Our reports have been used by over 10K customers, including:
Measles - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Measles - Pipeline Review, H2 2020, provides an overview of the Measles (Infectious Disease) pipeline landscape. Measles is a highly infectious viral disease. The virus lives in the...
Rabies Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Rabies Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Rabies Clinical trials scenario.This report provides top line data relating to the clinical trials on Rabies. Report includes...
The global cancer vaccines market is expected to reach US$ 15,845.59 million by 2027 from US$ 4,568.82 million in 2019; it is estimated to grow at a CAGR of 17.2% from 2020 to 2027. The growth of the cancer vaccines market is mainly attributed to the globally increasing incidence of cancer and rising number of initiatives related to...
Respiratory Disease Vaccine Market Research Report by Infection (Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis), by Type (Bacterial Vaccine, Combination Vaccine, and Viral Vaccine), by Age Group - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Respiratory Disease Vaccine...
Rotavirus Infections - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape. Rotavirus is a virus that infects...
United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies The average human life span has grown significantly primarily due to vaccination. Vaccines have transformed public health throughout...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.